Callisto Anti-Cancer Drug Atiprimod Chosen for 2nd High-Profile Oral Presentation at American Society of Hematology Meeting
30th Nov 2005, 17:29 GMT
Callisto Pharmaceuticals, a developer of new drug treatments in the fight against cancer and other serious health threats, announced that its anti-cancer drug candidate Atiprimod has been further recognized by the scientific community with selection for a 2nd Oral presentation of research data, abstract, at the annual meeting of American Society of Hematology, the field's most important scientific organization, held next month in Atlanta, GA.
Callisto Anti-Cancer Drug Atiprimod Chosen for 2nd High-Profile Oral Presentation at American Society of Hematology Meeting related news:
- Callisto Pharmaceuticals Announces Poster Presentation on Atiprimod at Scientific Meeting in December — Pharmaceuticals News from StratCenter.com
- Gloucester Pharmaceuticals Announces Presentations of Depsipeptide (FK228) Data at the 47th Annual Meeting of The American Society of Hematology — RedOrbit News - Health
- Accentia Biopharmaceuticals Announces That Follow-up Data from the Phase II Clinical Trial of BiovaxID Will Be Presented at the Annual Meeting of the American Society for Hematology — StratWire - Business of Healthcare NewsFeed
- Biovest Int'l Will Report New Follow-up Data from Its Phase 2 Clinical Trial of BiovaxID at the Annual Meeting of the American Society for Hematology — StratWire - Business of Healthcare NewsFeed
- Bionovo Announces Presentation on Its Lead Anti-Cancer Compound at Upcoming San Antonio Breast Cancer Symposium — Radiology News from StratCenter.com
- Smokers at greater risk of oral cancer — HEALTH
- New breast cancer drug shows promise — The Cancer Blog
- Gray receives award from American Cancer Society — The Oakridger
- Oral cancer: One more reason my sister-in-law is happy she quit smoking — The Cancer Blog
- Major Ovarian Cancer Clinical Study Announced At Yale Using Combination Drug Therapy — ScienceDaily Headlines
Latest news from Laboratory News from StratCenter.com:
- Abstract Evaluating QUADRAMET for Multiple Myeloma Presented erican Society of Hematology Annual Meeting
- QIAGEN Introduces Novel Technology for Customized RNAi Assay Products
- Stratagene Reports Q3 Results
- Viking Systems Appoints Dr Michael Manyak to Its Board
- Soliant Health To Exhibit at the American Speech-Language-Hearing Assoc Conference
- Sysmex America Awarded Contract to Service VA Med Cntrs in Midwest States
- Ronald D Luff, MD, Recognized By the American Society of Cytopathology for Groundbreaking Work in Diagnosis of Cervical Disease
- INNOVIVE Pharmaceuticals Reports Q3 Results
- Launch of 'Egg Banking' Program Breaks New Ground as 1st Program of Its Kind in NC
- Global Care Quest Announces ICIS 5